SCHEMBL8724153

SCHEMBL8724153

CCS(=O)(=O)c1cccc(C(=O)Nc2ccc3scc(C4=CCN5CCCCC5CC4)c3c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
BLM P54132 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
TDP1 Q9NUW8 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CNR1 P21554 1/20 0.37
GAA P10253 2/20 0.37
MAPK1 P28482 2/20 0.37
LMNA P02545 2/20 0.37
KDM4A O75164 1/20 0.36
KDM4B O94953 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
ALDH1A1 P00352 4/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
USP2 O75604 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8723604 0.89 TDP1 (0.39) RXFP1MEN1KMT2ATDP1L3MBTL1
SCHEMBL8725926 0.89 TDP1 (0.41) POLBRXFP1MEN1KMT2ATDP1
SCHEMBL8720823 0.88 TDP1 (0.39) RXFP1MEN1KMT2ATDP1L3MBTL1
SCHEMBL8720711 0.87 TP53 (0.44) MEN1KMT2ATDP1GAAMAPK1
SCHEMBL8721851 0.86 TDP1 (0.38) TDP1L3MBTL1GAAMAPK1LMNA
SCHEMBL8720693 0.85 NPC1 (0.44) MEN1KMT2ATDP1GAAMAPK1
SCHEMBL8723878 0.84 NR1H4 (0.46) MEN1KMT2ATDP1L3MBTL1LMNA
SCHEMBL8721285 0.82 KCNQ3 (0.40) POLBMEN1KMT2ALMNANPC1
SCHEMBL8724021 0.82 HTR1F (0.40) MAPK1NPC1RAB9ASMN1; SMN2HTT
SCHEMBL8720679 0.82 MAPK14 (0.38) KMT2ATDP1L3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D POLB 3187/4885BLM 1597/4885RXFP1 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.